Literature DB >> 19521690

Synthesis and characterization of a new fluorogenic substrate for alpha-galactosidase.

Zhen-Dan Shi1, Omid Motabar, Ehud Goldin, Ke Liu, Noel Southall, Ellen Sidransky, Christopher P Austin, Gary L Griffiths, Wei Zheng.   

Abstract

Alpha-galactosidase A hydrolyzes the terminal alpha-galactosyl moieties from glycolipids and glycoproteins in lysosomes. Mutations in alpha-galactosidase cause lysosomal accumulation of the glycosphingolipid, globotriaosylceramide, which leads to Fabry disease. Small-molecule chaperones that bind to mutant enzyme proteins and correct their misfolding and mistrafficking have emerged as a potential therapy for Fabry disease. We have synthesized a red fluorogenic substrate, resorufinyl alpha-D-galactopyranoside, for a new alpha-galactosidase enzyme assay. This assay can be measured continuously at lower pH values, without the addition of a stop solution, due to the relatively low pK(a) of resorufin (approximately 6). In addition, the assay emits red fluorescence, which can significantly reduce interferences due to compound fluorescence and dust/lint as compared to blue fluorescence. Therefore, this new red fluorogenic substrate and the resulting enzyme assay can be used in high-throughput screening to identify small-molecule chaperones for Fabry disease.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19521690      PMCID: PMC2756488          DOI: 10.1007/s00216-009-2879-5

Source DB:  PubMed          Journal:  Anal Bioanal Chem        ISSN: 1618-2642            Impact factor:   4.142


  17 in total

1.  A STUDY OF YEAST ALPHA-GALACTOSIDASE WITH NAPHTHYL ALPHA-D-GALACTOPYRANOSIDES AS CHROMOGENIC SUBSTRATES.

Authors:  K C TSOU; H C SU
Journal:  Anal Biochem       Date:  1964-08       Impact factor: 3.365

2.  Fluorescence spectroscopic profiling of compound libraries.

Authors:  Anton Simeonov; Ajit Jadhav; Craig J Thomas; Yuhong Wang; Ruili Huang; Noel T Southall; Paul Shinn; Jeremy Smith; Christopher P Austin; Douglas S Auld; James Inglese
Journal:  J Med Chem       Date:  2008-03-26       Impact factor: 7.446

3.  Role of Ser-65 in the activity of alpha-galactosidase A: characterization of a point mutation (S65T) detected in a patient with Fabry disease.

Authors:  S Ishii; Y Suzuki; J Q Fan
Journal:  Arch Biochem Biophys       Date:  2000-05-15       Impact factor: 4.013

Review 4.  Clinical results of enzyme replacement therapy in Fabry disease: a comprehensive review of literature.

Authors:  O Lidove; D Joly; F Barbey; S Bekri; J-F Alexandra; V Peigne; R Jaussaud; T Papo
Journal:  Int J Clin Pract       Date:  2007-02       Impact factor: 2.503

Review 5.  Enzyme replacement for lysosomal diseases.

Authors:  Roscoe O Brady
Journal:  Annu Rev Med       Date:  2006       Impact factor: 13.739

Review 6.  Active-site-specific chaperone therapy for Fabry disease. Yin and Yang of enzyme inhibitors.

Authors:  Jian-Qiang Fan; Satoshi Ishii
Journal:  FEBS J       Date:  2007-10       Impact factor: 5.542

7.  Mutant alpha-galactosidase A enzymes identified in Fabry disease patients with residual enzyme activity: biochemical characterization and restoration of normal intracellular processing by 1-deoxygalactonojirimycin.

Authors:  Satoshi Ishii; Hui-Hwa Chang; Kunito Kawasaki; Kayo Yasuda; Hui-Li Wu; Scott C Garman; Jian-Qiang Fan
Journal:  Biochem J       Date:  2007-09-01       Impact factor: 3.857

8.  Screening for pharmacological chaperones in Fabry disease.

Authors:  Sang-Hoon Shin; Gary J Murray; Stefanie Kluepfel-Stahl; Adele M Cooney; Jane M Quirk; Raphael Schiffmann; Roscoe O Brady; Christine R Kaneski
Journal:  Biochem Biophys Res Commun       Date:  2007-05-22       Impact factor: 3.575

9.  Long-term safety and efficacy of enzyme replacement therapy for Fabry disease.

Authors:  William R Wilcox; Maryam Banikazemi; Nathalie Guffon; Stephen Waldek; Philip Lee; Gabor E Linthorst; Robert J Desnick; Dominique P Germain
Journal:  Am J Hum Genet       Date:  2004-05-20       Impact factor: 11.025

10.  Characterization of a mutant alpha-galactosidase gene product for the late-onset cardiac form of Fabry disease.

Authors:  S Ishii; R Kase; H Sakuraba; Y Suzuki
Journal:  Biochem Biophys Res Commun       Date:  1993-12-30       Impact factor: 3.575

View more
  6 in total

1.  A high-throughput sphingomyelinase assay using natural substrate.

Authors:  Miao Xu; Ke Liu; Noel Southall; Juan J Marugan; Alan T Remaley; Wei Zheng
Journal:  Anal Bioanal Chem       Date:  2012-06-19       Impact factor: 4.142

2.  Fabry disease - current treatment and new drug development.

Authors:  Omid Motabar; Ellen Sidransky; Ehud Goldin; Wei Zheng
Journal:  Curr Chem Genomics       Date:  2010-07-23

3.  An alternative direct compound dispensing method using the HP D300 digital dispenser.

Authors:  Raisa E Jones; Wei Zheng; John C McKew; Catherine Z Chen
Journal:  J Lab Autom       Date:  2013-05-24

4.  Activatable Optical Probes for the Detection of Enzymes.

Authors:  Christopher R Drake; David C Miller; Ella F Jones
Journal:  Curr Org Synth       Date:  2011-08       Impact factor: 1.975

5.  High throughput screening for inhibitors of alpha-galactosidase.

Authors:  Omid Motabar; Ke Liu; Noel Southall; Juan J Marugan; Ehud Goldin; Ellen Sidransky; Wei Zheng
Journal:  Curr Chem Genomics       Date:  2010-12-03

6.  Molecular switching system using glycosylphosphatidylinositol to select cells highly expressing recombinant proteins.

Authors:  Emmanuel Matabaro; Zeng'an He; Yi-Shi Liu; Hui-Jie Zhang; Xiao-Dong Gao; Morihisa Fujita
Journal:  Sci Rep       Date:  2017-06-22       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.